Login to Your Account


Pharnext inks three-part pact with China's Tasly

By Nuala Moran
Staff Writer

Wednesday, May 17, 2017

LONDON – In a Franco-Sino tie-up Pharnext SA and Tasly Pharmaceutical Co. Ltd. signed a three-part agreement, which will see the Chinese pharma invest up to $44 million in a combination of equity, a joint venture, and the clinical development of Pharnext's lead program, PXT-3003, in China.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription